All News
Filter News
Found 104 articles
-
Clinical Catch-Up: October 28-Nov 1
11/4/2019
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. -
NetNoggin® releases exploratory analysis "Alzheimer's Recent Drug Failures"
10/2/2019
NetNoggin® analyzes big data to better understand why Alzheimer's drugs fail clinical trials and how the Alzheimer's community reacts to the failures.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
BridgeBio launched Charlotte, N.C.-based ML Bio Solutions to develop the LGMD2i asset BBP-418, a substrate supplementation therapy.
-
According to the U.S. Centers for Disease Control and Prevention, about 2 million people each year are infected with antibiotic-resistant bacteria and 23,000 people die as a result. A recent study by the UK government estimated that by 2050, as many as 10 million people could die worldwide from a...
-
There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?
-
Clinical Catch-Up for July 8-12
7/15/2019
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look. -
Earlier this week, Biogen reported out its first-quarter financial results, showing an 11% increase in revenues, hitting $3.5 billion. But in light of the company’s announcement in late March that it was dropping development of aducanumab for Alzheimer’s, analysts are speculating on what the comp...
-
Blackstone Life Sciences, a private investment firm, along with Novartis, launched Anthos Therapeutics with a $250 million investment. Anthos will be headquartered in Cambridge, Mass.
-
Ovid CEO Jeremy Levin Puts the Patient First as He Seeks to Revolutionize Drug Development in Neu...
1/28/2019
As the chief executive officer of Ovid Therapeutics, Jeremy Levin has a lot on his plate. But, there is one thing always in the forefront of Levin’s mind – the patients his company can serve. -
PwC recently came out with the latest version of their annual R&D spending report, and while there is a lot of interesting information to digest in this report, there are a few companies in particular that stand out within the field of biotechnology.
-
Turning an existing partner into a wholly owned subsidiary, Novartis is acquiring CellforCure from biotechnology group LFB for an undisclosed figure.
-
Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
12/17/2018
PTX-022 is a late-stage drug candidate targeting pachyonychia congenita
-
Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.
-
What’s Going on With the Biosimilar Market?
12/10/2018
Although a moderate presence in Europe, with about 25 biosimilars approved and on the market, they haven’t gained traction in the U.S. Even though at least 11 have been approved in the U.S., only about three are available, largely because of business tactics branded drug companies are using to sl... -
Novartis has been on something of a housecleaning binge since Vasant (Vas) Narasimhan took over the chief executive officer position from Joseph Jimenez in January of this year. On October 30, Novartis indicated it planned to abandon approximately 20 percent of its research projects.
-
Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
11/15/2018
Adrian Adams To Serve as Independent Chairperson of the Board After Merger
-
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the c...
-
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos' Filgotinib Inches Toward Appr...
9/6/2018
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS). -
Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling Hi...
8/23/2018
Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events.